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Abstract This systematic review explores the effects of
dysphagia treatment for Parkinson’s disease. The review
includes rehabilitative, surgical, pharmacologic, and other
treatments. Only oropharyngeal dysphagia is selected for
this literature search, excluding dysphagia due to esopha-
geal or gastric disorders. The effects of deep brain
stimulation on dysphagia are not included. In general, the
literature concerning dysphagia treatment in Parkinson’s
disease is rather limited. Most effect studies show diverse
methodologic problems. Multiple case studies and trials are
identified by searching biomedical literature databases
PubMed and Embase, and by hand-searching reference
lists. The conclusions of most studies cannot be compared
with one another because of heterogeneous therapy meth-
ods and outcome measures. Further research based on
randomized controlled trials to determine the effectiveness
of different therapies for dysphagia in Parkinson’s disease
is required.
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Dysphagia is a frequent symptom of Parkinson’s disease
[1–3] and is often associated with considerable morbidity
and mortality due to nutritional and pulmonary complica-
tions [1, 2]. Dysphagia is observed more often in patients
with an advanced stage of Parkinson’s disease [4]. In the
literature, the prevalence of dysphagia varies from 18.5 to
100% [2, 3]. However, as many as 15% of the patients with
Parkinson’s disease show silent aspiration and do not
complain of dysphagia [1]. The pathologic mechanisms of
oropharyngeal dysphagia in Parkinson’s disease are not
quite clear. Oropharyngeal bradykinesia and rigidity,
incomplete cricopharyngeal relaxation, reduced cricopha-
ryngeal opening, and delayed initiation of the swallowing
reflex have been suggested as possible mechanisms of
dysphagia in this patient population [1, 4]. Among the
different therapies for dysphagia in Parkinson’s disease,
rehabilitative treatment (swallowing training), cricopha-
ryngeal sphincterotomy, and pharmacologic therapies have
been reported.
The number of reports on the effects of therapies for
dysphagia in Parkinson’s disease is still rather small. This
article is a systematic review of the literature on the effects
of treatment for dysphagia in Parkinson’s disease. Deane
et al. [5] published a systematic review on nonpharmaco-
logic therapies for dysphagia in Parkinson’s disease;
however, the present systematic review incorporates all
therapies available for oropharyngeal dysphagia in Par-
kinson’s disease, including an update on rehabilitative
therapies. The different types of therapy are grouped into
four main therapy groups: rehabilitative, surgical, phar-
macologic, and other.
Methods
The two authors independently carried out the literature
search using the electronic literature databases Embase and
PubMed. Differences in their search were settled by dis-
cussion. The search was limited to English, German,
French, Spanish, and Dutch language publications. In
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Embase the Mesh terms swallowing or dysphagia were
combined with Parkinsonism or Parkinson-disease. In
PubMed the Mesh terms Parkinson disease or Parkinson
disease, secondary or Parkinsonian disorders were com-
bined with deglutition disorders. To identify the most
recent publications, the search was supplemented by using
free-text words (truncation or wildcard) in Embase and
PubMed (for the period after January 2005 up to May
2008): deglut* or swallow* or dysphag* were combined
with hypokinetic syndrome or Parkinson* or Paralysis
agitans. A total of 602 articles were found in Embase and
258 articles in PubMed. Only articles on the effects of
therapy for oropharyngeal dysphagia in Parkinson’s disease
were included. Studies describing heterogeneous subject
populations that included patients with Parkinson’s disease
and patients with other neurologic diseases were excluded
[6], except those studies that presented both pre- and
posttreatment data per subgroup [7]. Patients receiving
deep brain stimulation were excluded. It was decided to
exclude deep brain stimulation because dysphagia has been
described as a side effect of this therapy [8]. Studies using
a subject population of fewer than three were excluded [9–
11]. The relevance and level of evidence of studies based
on populations of fewer than three subjects is doubtful.
Percutaneous endoscopic gastrostomy (PEG) tube feeding
was excluded as treatment for dysphagia because it is a
feeding substitute. There were no limitations on disease
duration or disease severity. Articles with subjects of all
ages and any duration of treatment were selected. After a
first selection based on abstracts, a definitive inclusion was
made using the original articles. The reference lists of all
the included articles were searched for additional literature.
This search did not provide additional studies. In conclu-
sion, 16 articles were included in this review.
Results
Table 1 presents a summary of the 16 articles that describe
rehabilitative, surgical, pharmacologic, or other therapies
for dysphagia in Parkinson’s disease. The first column of
the table represents the level of evidence. To rate the study
quality, the ABC rating scale according to Siwek et al. [12]
was used. Level A refers to high-quality randomized con-
trolled trials; level B refers to well-designed,
nonrandomized clinical trials, and level C refers to con-
sensus or expert opinions. Categories A and B were
subdivided into two groups according to the way data were
handled. The first group used statistical analyses for com-
paring pre- versus posttherapy data. The second group used
descriptive statistics to evaluate the therapy outcome.
Level C reflects an expert’s opinion without presentation of
any statistical data. Authors were listed in alphabetical
order. The following data were summarized (if present) for
each article: the number of patients, the disease severity
based on the Hoehn and Yahr scale (H-Y scale) [13], the
kind of therapy used, the evaluation techniques, outcome
parameters, blinded rater(s), on/off-motor phase, and the
authors’ key findings. The fluctuation in daily performance
of Parkinson patients on long-term L-dopa therapy is
known as the ‘‘on/off’’ phenomenon [14]. The number of
subjects refers to the group of subjects on which the study
results were based, i.e., dropouts were excluded. All studies
were described briefly.
Rehabilitative Treatment (Swallowing Training)
Studies to determine the effects of swallowing training in
Parkinson’s disease are extremely rare. El Sharkawi et al.
[15] studied the effects of 1 month of Lee Silverman Voice
Treatment (LSVT) on swallowing and voice in eight
patients with idiopathic Parkinson’s disease and dysphagia.
The treatment was conducted four times a week at 50–
60 min per session. The effectiveness of the LSVT was
evaluated by comparing pre- and posttherapy measure-
ments, including a lateral videofluoroscopy of swallowing
conducted at the same time of day and medicine cycle for
each patient. One rater, who was blinded to the therapy
used, performed the swallow analysis. Outcome parameters
consisted of temporal and qualitative measures of swal-
lowing. Disease severity according to the H-Y scale and
statistical analysis were described. After 1 month of LSVT,
the authors concluded that LSVT seemed to be effective in
improving neuromuscular control of the entire upper ae-
rodigestive tract, improving oral tongue and tongue base
function during the oral and pharyngeal phases of
swallowing.
In a study by Nagaya et al. [4], the authors tried to
determine whether swallowing training, consisting of five
motor function/behavioral exercises, improved swallowing
function in ten patients with Parkinson’s disease and dys-
phagia. The swallowing training took about 20 min. There
was only one session of exercises. The premotor time
(PMT) was evaluated pre- and posttherapy during the on-
motor phase using electromyography (EMG). The PMT
was defined as the latency of EMG activity when a specific
movement was requested in response to an imperative
stimulus, reflecting the time for information processing in
the sensorimotor pathways. The modified barium swallow
study (MBS) was performed only before treatment to
assess the oral and pharyngeal functions in patients with
Parkinson’s disease. All examinations were performed
during the on-motor phase. Disease severity was mentioned
(H-Y scale) and a control population of 12 healthy vol-
unteers was used. It was not mentioned whether the pre-
versus posttreatment EMG results were scored blinded to
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the schedule of treatment. A statistically significant
decrease in PMT in patients with Parkinson’s disease was
observed after swallowing training, even though the
training was done only once. The initiation of the swal-
lowing reflex in patients with Parkinson’s disease and
dysphagia could be improved by swallowing training.
In the report by Pinnington et al. [16], the effects of
verbal cueing on the swallowing function while presenting
a spoon of liquid to the mouth (on-motor phase) were
evaluated by means of the Exeter Dysphagia Assessment
Technique (EDAT) in 12 patients with Parkinson’s disease
compared to 14 control patients on the orthogeriatric ward.
The EDAT recorded nasal airflow, contact of the lips or
tongue with a spoon, and sounds associated with swal-
lowing. Disease severity was scored according to the H-Y
disability scale and the Unified Parkinson’s Disease rating
scale. It was not mentioned whether the rating during the
EDAT was performed blinded to diagnosis and therapy.
After statistical analysis the authors concluded that the use
of verbal cueing resulted in a significant reduction in the
duration of the oral part of swallowing, but had no impact
on the duration of the pharyngeal part of swallowing or the
mean number of swallows.
Troche et al. [17] evaluated the effect of bolus consis-
tency on timing and safety of swallowing in patients with
Parkinson’s disease. The severity of the disease was scored
using the H-Y scale. During videofluoroscopy, ten Par-
kinson patients completed a dry swallow, six 5-cc trials of
pudding-thick liquid, and six 5-cc trials of thin liquid. The
trials were presented in random order. Swallowing was
analyzed using qualitative (penetration-aspiration scale
[P-A] by Rosenbek et al. [18] and number of tongue
pumps) and quantitative (timed variables) swallowing
parameters. Patients were tested 1 h after medication dur-
ing the on-motor phase. The examiner was blinded to the
patients’ identity. Analysis revealed significant differences
between oral transit time, number of tongue pumps, and
penetration-aspiration scale with respect to bolus consis-
tency. Oral transit time and the number of tongue pumps
increased with thicker boluses and the P-A score was
higher for thinner boluses. No significant differences were
found for pharyngeal transit time.
Logemann et al. [7] performed a study to identify which
of three treatments for aspiration on thin liquids (chin-
down posture, nectar-thickened liquids, or honey-thickened
liquids) resulted in the most successful immediate elimi-
nation of aspiration during a videofluoroscopic swallow
study in patients with dementia and/or Parkinson’s disease.
Two hundred twenty-eight Parkinson patients underwent
all three interventions in randomly assigned order. The H-
Y scale was used. The outcome parameter during video-
fluoroscopy was a qualitative variable (aspiration) of
swallowing. No information about the on/off-motor phase
during measurements was given. Thirty-nine percent of
participants with Parkinson’s disease without dementia
aspirated on all three interventions. Twelve percent aspi-
rated on two of the three interventions. Seventeen percent
aspirated on one of the three interventions. Thirty-two
percent aspirated on none of the three interventions. Based
on these descriptive results the authors concluded that the
most frequently successful intervention to eliminate thin-
liquid aspiration immediately was the honey-thickened
liquid, followed closely by the nectar-thickened liquid and
then the chin-down posture.
Surgical Treatment
Two articles provided anecdotal data about surgical treat-
ment for dysphagia in Parkinson’s disease. In the articles
by Born et al. [19] and Byrne et al. [20], cricopharyngeal
sphincterotomy was performed in very small groups of
patients. Born et al. [19] described four patients who
experienced excellent and sustained relief of esophageal
symptoms following surgery, providing further support for
the primacy of cricopharyngeal dysfunction in causing
dysphagia in these patients. The patients tolerated myot-
omy extremely well and none developed aspiration. Byrne
et al. [20] studied three patients with cricopharyngeal
dysfunction who had undergone cricopharyngeal myotomy
with excellent results. Only pretreatment measurements
consisting of manometry and videoesophagography were
performed in both studies. No posttreatment measurements
were described, although the authors’ own conclusions
were included. In contrast to Born et al. [19], Byrne et al.
[20] mentioned disease severity (H-Y scale).
Pharmacologic Treatment
Seven articles provided information about the effects of
antiparkinsonian drugs on the swallowing function.
Calne et al. [21] studied the effect of maximum toler-
ated doses of L-dopa on swallowing (range = 1–6.8 g/day)
compared to a placebo in 18 patients with idiopathic par-
kinsonism by means of lateral cineradiography. Data were
gathered for both L-dopa and placebo use in the same
patients. The outcome parameter was duration of pharyn-
geal deglutition. Patients and the radiologist were blinded
to therapy. Disease severity and on/off-motor phase were
not mentioned. Statistical analysis showed no significant
difference between the pharyngeal transit times during the
intake of L-dopa and of placebo. However, all patients
showed remarkably normal radiologic patterns of degluti-
tion before the onset of treatment; only 11 of 18 patients
suffered from subjective dysphagia.
Hunter et al. [22] studied the degree of dopaminergic
response of swallowing dysfunction in 15 patients with
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Parkinson’s disease. After a minimum of 8 h of withdrawal
from antiparkinsonian medication, the patients received a
single oral dose of 250 mg of levodopa plus 25 mg of
carbidopa on the first study day. The pretreatment MBS
was performed during the off-motor phase and the post-
treatment MBS during the on-motor phase. One week later
the sequence of medication was repeated using subcuta-
neous apomorphine (mean dose = 3.5 mg). Outcome
parameters consisted of qualitative measures of swallowing
function and timed components of swallowing. Two blin-
ded judges performed the rating of the MBS. No
information was given about the initial severity of the
disease of the included patients. For qualitative variables,
few significant differences were found after levodopa or
apomorphine. A significant reduction in oral preparatory
phase time with semisolids and thin fluids after levo-
dopa was observed, as well as a reduced pharyngeal
transit time with semisolids after apomorphine. Using
statistical analysis, the authors concluded that swallowing
dysfunction was predominantly resistant to dopaminergic
stimulation.
The study by Iwasaki et al. [23] described the positive
therapy effects of traditional Chinese medicine ‘‘Banxia
Houpo Tang’’ (BHT) in improving the swallowing reflex of
patients with Parkinson’s disease. They studied 28 patients
with a defined H-Y score and compared them to five
healthy controls of comparative age. They divided the
patients with Parkinson’s disease into two groups. Twenty-
two patients and the healthy controls were given BHT 1.5 g
three times a day for 4 weeks at 30 min before each meal
and six patients were given the same amount of lactate. The
evaluation tool used was submental electromyography
(EMG). Latency time of the swallowing reflex (timing
from the injection of the bolus to the onset of swallowing)
was used as the outcome parameter. The examiners did not
know which patients took BHT or lactate. Whether patients
were examined during an on/off-motor phase was not
mentioned. The EMG examinations before and after
treatment were performed at 11 a.m. After therapy a sta-
tistically significant decrease of swallowing reflex time was
demonstrated in the patient group receiving BHT. It
remains unclear which components in the extract of dried
plants were responsible for the improvement of the swal-
lowing function.
Lim et al. [24] studied the effect of the usual dose of
levodopa on the coordination of swallowing and respiration
in ten patients with Parkinson’s disease. The patients were
randomly assigned to group 1 or group 2. Group 1 had the
first assessment session during the on-motor phase and the
second assessment session during the off-motor phase.
Group 2 had the first session during the off-motor phase
and the second during the on-motor phase. The two ses-
sions during ‘‘on’’ and ‘‘off’’ were performed in the
morning at least 1 week apart. The assessment consisted of
EMG with a nasal cannula and an endoscopic evaluation of
swallowing (FEES). A dysphagia quality-of-life question-
naire (SWAL-QOL) was filled out only before treatment
[25]. Disease severity according to the H-Y scale and sta-
tistical analysis were described. No information was given
whether the results of the EMG and FEES were scored
blinded to therapy. After statistical analysis the authors
concluded that swallowing efficiency might be reduced
with levodopa medication. No association was found
between levodopa and coordination of swallowing and
respiration, laryngeal penetration, or tracheal aspiration,
indicating that the risk of aspiration may remain unchan-
ged. According to the authors, further studies comprising
larger numbers of patients are needed to determine whether
the trend in swallowing efficiency is a true effect and to
confirm if there really is no difference in risk of aspiration
between ‘‘on’’ and ‘‘off’’ states of levodopa.
Tison et al. [26] studied the effects of apomorphine (in
combination with domperidone) on buccolinguofacial mo-
toricity and on various swallowing stages by using
videofluoroscopy in eight patients with Parkinson’s disease
and dysphagia. The severity of the disease was scored by the
H-Y scale. The pre- and posttherapy assessments included a
buccolinguofacial motor function test and videofluoroscopy
of swallowing analyzed using qualitative and quantitative
swallowing parameters. Only a subjective self-rating of the
dysphagia severity on a 10-point scale was carried out
pretreatment. Pretreatment measurements were performed
during the off-motor phase after overnight withdrawal of
medication. Posttreatment measurements were performed
during the on-motor phase. It was not mentioned whether
rating of the videofluoroscopic examinations was per-
formed blinded to therapy or by how many judges. After
statistical analysis the authors found statistically significant
results indicating that central dopaminergic stimulation by
apomorphine improves swallowing abnormalities and
restricts total swallowing time in a subgroup of patients
with Parkinson’s disease and swallowing disorders. This
improvement was correlated mainly with improvement of
the early stages of swallowing and improvement of the
buccolinguofacial motor score. However, the interindivid-
ual variations and differential effects on the various
swallowing stages must be investigated in a larger patient
population in order to detect statistically significant
differences.
In contrast to the previous four articles that used sta-
tistical analysis, the following two studies provided
descriptive data about the effects of levodopa on the
swallowing function.
In the study by Bushmann et al. [27], the effects of the
intake of the usual dose of levodopa were evaluated by
means of pre- and posttreatment MBS in 20 patients with
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Parkinson’s disease. The severity of the disease was scored
by the H-Y scale. The number of subjects with Parkinson’s
disease who were included in the data analysis was not
clear. Only 15 of 20 patients had abnormal swallows on
MBS before therapy. A second therapy consisting of a
voluntary airway protection technique for the mechanical
modification of swallowing was applied to three patients. It
was not clear whether these three patients also participated
in the levodopa trial. An oral motor screening exam and
Logemann’s bedside dysphagia evaluation were performed
only pretherapy. A control group of 13 subjects with no
clinical evidence of neurologic or swallowing abnormality
was recruited. The pretreatment MBS was performed dur-
ing the off-motor phase and the posttreatment MBS during
the on-motor phase. A variety of swallowing behaviors
were assessed during the MBS by two speech pathologists,
of which one was blinded to diagnosis. A clear improve-
ment in swallowing in 5 of the 15 patients following an oral
dose of levodopa was observed. The voluntary airway
protection technique eliminated aspiration in two of three
patients. According to the authors, higher doses of levo-
dopa did not provide additional benefit.
Fuh et al. [28] examined the oropharyngeal swallowing
ability in 19 Parkinson’s disease patients using MBS before
and after administering oral levodopa (200 mg) in combi-
nation with benserazide (50 mg). Salivation and subjective
swallowing difficulty were graded on a 5-point scale pre-
treatment. Salivation was graded as follows: 0 = normal,
1 = slight but definite excessive saliva in mouth with pos-
sible nighttime drooling, 2 = moderately excessive saliva
with minimal drooling, 3 = marked excessive saliva with
some drooling, 4 = marked drooling requiring constant use
of tissue or handkerchief. Subjective swallowing difficulty
was scored on a 5-point scale as well: 0 = normal, 1 = rare
choking, 2 = occasional choking, 3 = requiring soft food,
4 = requiring nasogastric or percutaneous endoscopic gas-
trostomy (PEG) tube feeding. The pretreatment MBS was
performed during the off-motor phase and the posttreatment
MBS during the on-motor phase. The severity of Parkin-
son’s disease was determined using the H-Y scale and the
Schwab and England scores. The judge who rated the
radiologic recordings was blinded to the severity of the
disease but was not blinded to the time the drugs were taken.
Twelve of 19 patients had abnormal swallows on MBS. Six
of these 12 patients showed improvement after taking
levodopa. Three of 19 patients showed aspiration on MBS.
Two of these three revealed no post-levodopa aspiration. It
was not clear whether these three patients overlapped with
the 12 patients with abnormal swallows. Based on descrip-
tive statistics, the authors concluded that more than half of
the patients experienced improved swallowing function
after levodopa treatment due to a reduction of bradykinesia
and rigidity of the tongue.
Other Treatments
Heckmann et al. [29] studied the benefit of using dental
implants combined with overdentures to improve chewing
and preingestion capacity in three severely handicapped
Parkinson patients. Disease severity was scored according
to the H-Y scale. Gastrointestinal (GI) symptoms were
assessed pre- and posttreatment using a modified symptom
questionnaire described by Horrowitz et al. [30]. Five GI
symptoms, i.e., abdominal bloating, heartburn, dysphagia,
regurgitation, and constipation, were evaluated on a 4-point
severity scale. Body weight was measured before and after
therapy. A self-rating scale for chewing abilities was filled
out after therapy. It was not described whether the GI
symptom score and the self-rating scale for chewing abil-
ities were performed during the on-motor phase. The
authors interpreted improved chewing capacity, a moderate
gain in body weight, and an improved GI score as signs of
improved predigestion.
In the study by Restivo et al. [31], the effect of percu-
taneous injected botulinum toxin for cricopharyngeal
dysfunction was evaluated in four patients with Parkinson’s
disease by means of videofluoroscopy of swallowing and
electromyography. No information was given about the
severity of the disease, the on/off-motor phase during
measurements, statistics, or whether the rater(s) were
blinded to therapy. The method of rating the videofluo-
roscopy was not described precisely (visuoperceptual?).
The authors concluded that given its safety and effective-
ness, the treatment with botulinum neurotoxin type A may
be a successful alternative to invasive procedures or may
be a useful tool for identifying patients who might benefit
from surgical myotomy.
Conclusion
Methodologic Problems
According to the ABC rating scale of Siwek et al. [12],
none of the included articles were level A (randomized
controlled trial). Thirteen of the included articles repre-
sented level B (nonrandomized clinical trial); however,
some of these studies included very small subject popula-
tions (e.g., Heckmann et al. [29]). Three articles
represented level C (expert’s opinion). Of the ABC rating
scale, level C (expert’s opinion/consensus) provides the
least evidence for key clinical recommendations. The
included studies on the effects of dysphagia treatment in
patients with Parkinson’s disease varied in quality of design
and most of the included studies had at least one method-
ologic shortcoming that may have introduced bias. In two
articles the therapy effects were evaluated positively by the
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authors despite the fact that only pretreatment examinations
were performed [19, 20]. These articles provided no evi-
dence of efficacy because of the missing posttherapy
measurements.
Some studies did not have an adequate method of ran-
domization for referral to different intervention groups,
e.g., Iwasaki et al. [23] and Bushman et al. [27] did not
score pre- versus posttreatment blinded for the schedule of
treatment [4, 24, 26–28], nor did they have an adequate
placebo or control population [7, 15, 17, 22, 26–29]. Very
often a control group receiving no therapy for dysphagia
when in fact an indication for treatment is present is
regarded as unethical and therefore usually not approved
by any medical ethical committee. Repeated baseline
measurements during the waiting period between the
referral for therapy and the actual therapy onset could
compensate this shortcoming more or less.
Selection bias might be a methodologic shortcoming in
some studies. Despite the fact that the control group had
neither a history of dysphagia nor evidence of neurologic
or respiratory disease, the use of a rather aged subject
population (such as the mean subject’s age of 78 years in
Pinnington’s study [16]) makes the presence of dysphagia
without subjective complaints more likely. Calne et al. [21]
described the effect of maximum tolerated doses of L-dopa
on the duration of the pharyngeal phase as outcome.
However, pretherapy the pharyngeal phase showed normal
radiologic patterns. Now it seems as if L-dopa failed to
have an effect in an already normal radiologic pattern of
deglutition, whereas the information of the total swallow-
ing act was incomplete. In some articles no information
was given about the Parkinson’s disease severity scale [19,
21, 22, 31]. Some authors did not describe the ‘‘on’’ or
‘‘off’’-motor phase during the examinations and therapy
[7, 19–21, 23, 29, 31].
Many studies were unbalanced as a result of small
sample sizes. Only seven of the 16 studies described in this
review included more than ten subjects (maximum
N = 228). Four studies used less than five subjects. Such a
small number of subjects restricts the possibility to find
statistically significant therapy effects. Furthermore, the
justification of the generalization of study outcomes to
patients with Parkinson’s disease in general or to any other
patient population with dysphagia can be questioned.
As far as the evaluation tools used to evaluate the
therapy effects on dysphagia, the majority of the studies
focused on the results found using just one tool [4, 7, 15,
17, 21–23, 27, 28]. As a consequence, certain aspects of the
swallowing act may be missed, such as decreased sensory
components of swallowing only detectable during
FEES(ST) or a patient’s subjective evaluation as measured
by a quality-of-life questionnaire. In the literature, diverse
evaluation instruments have been used to evaluate therapy
effects in dysphagia. When using a restricted set of
instruments, the information on therapy outcome will be
restricted as well. Poorly defined outcome parameters [19–
21, 31] and inadequate statistical analysis were also causes
of reduced reliability.
In conclusion, because of the diversity in study designs,
dysphagia treatment, evaluation techniques, and patient
characteristics as well as many methodologic problems,
statistical pooling of data derived from different articles
was not possible.
Therapy Effects in Literature
The lack of sufficient evidence of the efficacy of different
treatments for dysphagia in Parkinson’s disease did not
suggest a lack of effect. Summarizing the literature, it can
be concluded that positive group tendencies might be
observed, although no generalized conclusions can be
drawn from these reports.
The literature on the effects of surgical therapy for
dysphagia is extremely limited. The outcomes of the
studies of the two included articles were described in
general positive statements by the authors. These state-
ments were not supported by any statistical proof. The
five studies on the rehabilitative treatments for dysphagia
provided positive tendencies. It would be interesting to
design such studies using large subject populations. The
seven articles on pharmacologic treatments had very
diverse types and doses of medication. Also, their study
designs were too diverse to perform statistical pooling of
data. Because of different methodologic problems, large
randomized controlled trials on pharmacologic treatment
for dysphagia were advised. The therapy effects of other
treatments such as implant-prosthodontic treatment and
percutaneous injection of botulinum neurotoxin type A in
the cricopharyngeal muscle on dysphagia were rather
interesting options in the treatment of dysphagia. How-
ever, in this field too large well-designed trials are
required.
Future Research
Recommendations for conducting future therapy trials on
the effects of different types of treatment for swallowing
disorders in Parkinson’s disease include the use of large
numbers of patients, adequate placebo therapy if possible, a
follow-up period after therapy, notation if patients are ‘‘on’’
or ‘‘off’’-motor phase during measurements and treatment,
and using outcome scales validated for dysphagia in
subgroups. Nonbiased selection of study participants is
necessary. An extended assessment that includes several
instruments will provide a more complete view of the
100 L. W. J. Baijens, R. Speyer: Therapy for Dysphagia in Parkinson’s Disease
123
complexity of therapy effects in dysphagia. An assessment
of therapy results might include a quality-of-life measure-
ment, an evaluation of the nutrition intake, an oral motor
function test, a FEES, and/or videofluoroscopy of swal-
lowing. Such a multidimensional assessment of the
swallowing function pre- and posttherapy is advised
because of the complementary aspects of different assess-
ment tools. When using visuoperceptual rating of, for
example, videofluoroscopic recordings, an expert panel
should be used, blinded to group of therapy as well as to
pre- or posttherapy conditions.
It can be concluded that large randomized controlled
trials with a multidimensional swallowing assessment are
necessary to assess the effectiveness of the different types
of dysphagia treatments in Parkinson’s disease.
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